| | References | Year | Age | Sex | Medical History | Other drug | Fenofibrate | BUN | Cr | CK |
| 1 |
Wu et al. [6] | 2009 | 52 | F | DL | | 200 mg, for 1 mo | 43.8 | | |
| 2 |
De Souza et al. [7] | 2009 | 54 | M | CRF, DL, HT, Hypothyroidism | | 200 mg, for 2 mo | 120 | 4.9 | 52749 |
| 3 |
Çetinkaya et al. [5] | 2008 | 60 | F | DM-II, HT, DL | | 200 mg, for NA | | 4.2 | 11867 |
| 4 |
Unal et al. [1] | 2008 | 56 | F | CAD, DL | Pravastatin | 200 mg, for 2 mo | 37 | 2.6 | 97392 | 58 | M | CABG, DL | Atorvastatin | 200 mg, for 1 mo | 36 | 3.6 | 96639 |
| 5 |
Yildiz et al. [8] | 2008 | 74 | M | CABG, HT, DL | | 267 mg, for 2 wk | 224 | 5.3 | 26680 |
| 6 |
Tahmaz et al. [9] | 2007 | 42 | F | HT, DL | | 250 mg, for 4 wk | 90 | 5.5 | 21000 |
| 7 |
Dedhia and Munsi [10] | 2007 | 68 | M | CABGx2, HT, DL | Rosuvastatin | 160 mg, for 3 wk | | 2.3 | 23665 |
| 8 |
Jacob et al. [11] | 2005 | 70 | M | DM-II, HT, DL, Hypothyroidism | Simvastatin | 160 mg, for 4 wk | | 2.7 | 10936 |
| 9 |
Ireland et al. [12] | 2005 | 67 | F | HT, DL | Rosuvastatin | 160 mg, for 2 wk | 58 | 3.6 | 13808 |
| 10 |
Kursat et al. [13] | 2005 | 63 | F | HT, DL, Hypothyroidism | Simvastatin | 200 mg, for 4 wk | 188 | 4.5 | 8842 |
| 11 |
Ghosh et al. [14] | 2004 | 58 | M | CAD, DL | | 200 mg, for 5 wk | | | 1129 |
| 12 |
Barker et al. [15] | 2003 | 56 | F | HT, DM-II, DL | | 200 mg, for 10 d | | 2 | 5632 |
| 13 |
Clouatre et al. [16] | 1999 | 57 | F | CRF, DL, HT, Hypothyroidism | | 200 mg, for 4 wk | | | 8850 | 55 | F | CRF, PCRD, DL, Hypothyroidism | Simvastatin | 200 mg, for 3 wk | | | 11360 |
|
|
BUN: blood urea nitrogen (mg/dl), Cr: creatinine (mg/dl), DM: diabetes mellitus, CRF: chronic renal failure, CK: serum creatine kinase (IU/L), HT: hypertension, DL: dyslipidemia, CAD: coronary artery disease, CABG: coronary artery by-pass graft, and PCRD: polycystic renal disease.
|